Xencor, Inc. (XNCR)
24.59
+0.09
(+0.37%)
USD |
NASDAQ |
Oct 09, 16:00
24.59
0.00 (0.00%)
After-Hours: 20:00
Xencor EPS Diluted (Quarterly) : -0.2864 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2864 |
| March 31, 2026 | -1.713 |
| December 31, 2025 | -0.0892 |
| September 30, 2025 | -0.081 |
| June 30, 2025 | -0.415 |
| March 31, 2025 | -0.6572 |
| December 31, 2024 | -0.6225 |
| September 30, 2024 | -0.7051 |
| June 30, 2024 | -1.070 |
| March 31, 2024 | -1.111 |
| December 31, 2023 | -0.3139 |
| September 30, 2023 | -0.4003 |
| June 30, 2023 | -0.3671 |
| March 31, 2023 | -1.017 |
| December 31, 2022 | -0.201 |
| September 30, 2022 | -0.5486 |
| June 30, 2022 | -0.5704 |
| March 31, 2022 | 0.3863 |
| December 31, 2021 | 1.211 |
| September 30, 2021 | -0.6888 |
| June 30, 2021 | 0.866 |
| March 31, 2021 | -0.0429 |
| December 31, 2020 | -0.2378 |
| September 30, 2020 | -0.2192 |
| June 30, 2020 | -0.6137 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.1418 |
| December 31, 2019 | -0.474 |
| September 30, 2019 | -0.1805 |
| June 30, 2019 | -0.2843 |
| March 31, 2019 | 1.380 |
| December 31, 2018 | -0.3236 |
| September 30, 2018 | 0.054 |
| June 30, 2018 | -0.4646 |
| March 31, 2018 | -0.6176 |
| December 31, 2017 | 0.1528 |
| September 30, 2017 | -0.4827 |
| June 30, 2017 | -0.1652 |
| March 31, 2017 | -0.3268 |
| December 31, 2016 | -0.21 |
| September 30, 2016 | -0.20 |
| June 30, 2016 | 1.13 |
| March 31, 2016 | -0.16 |
| December 31, 2015 | 0.19 |
| September 30, 2015 | -0.25 |
| June 30, 2015 | -0.22 |
| March 31, 2015 | -0.19 |
| December 31, 2014 | -0.04 |
| September 30, 2014 | -0.20 |
| June 30, 2014 | -0.16 |
| March 31, 2014 | -0.12 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| UroGen Pharma Ltd. | -0.2848 |
| MeiraGTx Holdings Plc | 1.713 |
| Regeneron Pharmaceuticals, Inc. | 12.23 |
| Ironwood Pharmaceuticals, Inc. | 0.3068 |
| Viking Therapeutics, Inc. | -1.101 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -21.73M |
| Revenue (Quarterly) | 51.22M |
| Total Expenses (Quarterly) | 72.95M |
| Enterprise Value | 1.535B |
| Gross Profit Margin (Quarterly) | 95.24% |
| Profit Margin (Quarterly) | -42.42% |
| Earnings Yield | -8.82% |
| Normalized Earnings Yield | -10.71 |